
FDA Approved Lipfendra, the First Oral PCSK9 Inhibitor, for High LDL
The July 15, 2026 approval of enlicitide turns an injection class costing thousands per year into a daily pill. Trial numbers, coverage questions, what's next.
Sector news category — verified health events only (FDA, guidelines, major studies)

The July 15, 2026 approval of enlicitide turns an injection class costing thousands per year into a daily pill. Trial numbers, coverage questions, what's next.

The June 17, 2026 approval of tebipenem lets some kidney-infection patients leave the infusion chair for a pill — if stewardship rules hold the line on use.

The May 22, 2026 approval of bulevirtide brings the entry-blocker used in Europe since 2020 to US adults with chronic hepatitis delta. Who should be tested.

The May 1, 2026 approval of epdegestrant targets ESR1-mutated HR-positive metastatic breast cancer. Why genomic testing at relapse decides who qualifies.

The April 1, 2026 approval of orforglipron brings GLP-1 weight-loss therapy to a daily tablet manufactured at standard scale. Efficacy, side effects, coverage.

The March 17, 2026 approval of icotrokinra blocks the IL-23 pathway orally. What patients should weigh on efficacy, monitoring, and coverage.